Patents by Inventor Daria Jean Hazuda

Daria Jean Hazuda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HIV DRUG COMBINATION FOR INCREASING BARRIER AGAINST RESISTANCE
    Publication number: 20210283161
    Abstract: The instant invention relates to a method for reducing the risk for development of anti-viral treatment resistance due to an HIV mutation in a human subject infected with HIV, comprising administering EFdA in combination with one or more anti-viral agents.
    Type: Application
    Filed: July 12, 2019
    Publication date: September 16, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Daria Jean Hazuda, Ming-Tain Lai
  • Assays using amyloid precursor proteins with modified ?-secretase cleavage sites to monitor ?-secretase activity
    Patent number: 7196163
    Abstract: Provided are methods of identifying inhibitors of ?-secretase that employ modified ?-secretase substrates. The modified ?-secretase substrates have ?-secretase cleavage sites that are altered from wild type. The amino acid sequences of the altered ?-secretase cleavage sites contain different amino acids in at least one of the positions P2-P1-P1?-P2? of the ?-secretase cleavage site. Many of the modified ?-secretase substrates are more efficient substrates for ?-secretase than are corresponding substrates having wild-type sequences, that is, these modified substrates are more susceptible to enzymatic breakdown by ?-secretase. Recombinant polynucleotide molecules encoding the modified ?-secretase substrates are provided. Antibodies that recognize cleavage products of the modified ?-secretase substrates are provided. Stable cell lines expressing the modified ?-secretase substrates are provided. Transgenic animals expressing the modified ?-secretase substrates are provided.
    Type: Grant
    Filed: April 30, 2003
    Date of Patent: March 27, 2007
    Assignee: Merk & Co., Inc.
    Inventors: Daria Jean Hazuda, Elizabeth Chen Dodson, Ming-Tain Lai, Min Xu, Xiao-Ping Shi, Adam J. Simon, Guoxin Wu, Yueming Li, Bruce Register
  • Assays using amyloid precursor proteins with modified beta-secretase cleavage sites to monitor beta-secretase activity
    Publication number: 20030200555
    Abstract: Provided are methods of identifying inhibitors of &bgr;-secretase that employ modified &bgr;-secretase substrates. The modified &bgr;-secretase substrates have &bgr;-secretase cleavage sites that are altered from wild type. The amino acid sequences of the altered &bgr;-secretase cleavage sites contain different amino acids in at least one of the positions P2-P1-P1′-P2′ of the &bgr;-secretase cleavage site. Many of the modified &bgr;-secretase substrates are more efficient substrates for &bgr;-secretase than are corresponding substrates having wild-type sequences, that is, these modified substrates are more susceptible to enzymatic breakdown by &bgr;-secretase. Recombinant polynucleotide molecules encoding the modified &bgr;-secretase substrates are provided. Antibodies that recognize cleavage products of the modified &bgr;-secretase substrates are provided. Stable cell lines expressing the modified &bgr;-secretase substrates are provided.
    Type: Application
    Filed: April 30, 2003
    Publication date: October 23, 2003
    Inventors: Daria Jean Hazuda, Elizabeth Chen Dodson, Ming-Tain Lai, Min Xu, Xiao-Ping Shi, Adam J. Simon, Guoxin Wu, Yueming Li, Robert Bruce Register
  • HIV integrase inhibitors
    Patent number: 6306891
    Abstract: Nitrogen-containing heteroaryl dioxo-butyric acid derivatives are described as inhibitors of HIV integrase and inhibitors of HIV replication. These compounds are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
    Type: Grant
    Filed: June 1, 1999
    Date of Patent: October 23, 2001
    Assignees: Merck & Co., Inc., Tularik Inc.
    Inventors: Harold G. Selnick, Melissa Egbertson, Daria Jean Hazuda, James P. Guare, Jr., John S. Wai, Steven D. Young, David L. Clark, Julio C. Medina
  • HIV INTEGRASE INHIBITORS
    Publication number: 20010014748
    Abstract: Compounds useful in the inhibition of HIV integrase, the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines are described. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described. Further, the culture Fusarium sp., MF6381 (ATCC 74469) is also disclosed, as well as processes for making compounds of structural formula I employing the culture Fusarium sp., MF6381 (ATCC 74469).
    Type: Application
    Filed: December 13, 1999
    Publication date: August 16, 2001
    Inventors: SHEO BUX SINGH, DEBORAH L. ZINK, DARIA JEAN HAZUDA, PETER J. FELOCK, JON DAVID POLISHOOK, ANNE W. DOMBROWSKI
  • HIV integrase inhibitors
    Patent number: 6271402
    Abstract: Compound of formula I: wherein the R groups are as defined by the specification. The compounds are useful in the inhibition of HIV integrase, the treatment of infection of HIV and treatment of AIDS.
    Type: Grant
    Filed: December 13, 1999
    Date of Patent: August 7, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Sheo Bux Singh, Deborah L. Zink, Daria Jean Hazuda, Peter J. Felock, Anne W. Dombrowski
  • Benzodiazepine hydrazide derivatives as inhibitors of HIV integrase
    Patent number: 5939414
    Abstract: Compounds having a benzodiazepine hydrazide core are described. These compounds are useful in the inhibition of HIV integrase, the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
    Type: Grant
    Filed: October 28, 1997
    Date of Patent: August 17, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Ian M. Bell, Daria Jean Hazuda, James P. Guare, Jr., Peter M. Munson, Wayne J. Thompson, Joseph P. Vacca
  • In vitro HIV integrase inhibitors
    Patent number: 5759842
    Abstract: Natural products such as equisetin and derivatives are described. These compounds are useful in the inhibition of HIV integrase.
    Type: Grant
    Filed: October 24, 1996
    Date of Patent: June 2, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Anne W. Dombrowski, Jeffrey C. Hastings, Daria Jean Hazuda, Jon David Polishook, Sheo Bux Singh